PTCT vs. SMMT, GMAB, ITCI, VTRS, MRNA, RDY, PCVX, SRPT, QGEN, and ASND
Should you be buying PTC Therapeutics stock or one of its competitors? The main competitors of PTC Therapeutics include Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Vaxcyte (PCVX), Sarepta Therapeutics (SRPT), Qiagen (QGEN), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
PTC Therapeutics vs.
Summit Therapeutics (NASDAQ:SMMT) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.
Summit Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Summit Therapeutics' return on equity.
PTC Therapeutics received 262 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 61.88% of users gave PTC Therapeutics an outperform vote while only 58.38% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.
Summit Therapeutics currently has a consensus target price of $33.57, suggesting a potential upside of 47.19%. PTC Therapeutics has a consensus target price of $58.85, suggesting a potential upside of 16.64%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than PTC Therapeutics.
Summit Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.
4.6% of Summit Therapeutics shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, PTC Therapeutics had 9 more articles in the media than Summit Therapeutics. MarketBeat recorded 13 mentions for PTC Therapeutics and 4 mentions for Summit Therapeutics. PTC Therapeutics' average media sentiment score of 0.50 beat Summit Therapeutics' score of 0.44 indicating that PTC Therapeutics is being referred to more favorably in the news media.
Summary
PTC Therapeutics beats Summit Therapeutics on 11 of the 19 factors compared between the two stocks.
Get PTC Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PTC Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:PTCT) was last updated on 2/21/2025 by MarketBeat.com Staff
